Best Biotech Stocks To Research - May 4th

Key Points

• Five biotech stocks to watch: MarketBeat's screener flagged Celcuity (CELC), Danaher (DHR), Vertex (VRTX), Rallybio (RLYB) and Moderna (MRNA) as the top biotech names by recent dollar trading volume.
• Biotech investing is high-risk, high-reward, so MarketBeat advises focusing on pipeline prospects, clinical-trial milestones, regulatory approvals, patent positions and cash runway rather than short-term earnings.
• The group spans different business models and risk profiles—from Danaher's bioprocessing and lab tools to Celcuity's CELsignia diagnostic platform, Vertex's established cystic fibrosis therapies, Rallybio's clinical-stage FNAIT candidates, and Moderna's broad mRNA vaccine and therapeutic pipeline.

Celcuity, Danaher, Vertex Pharmaceuticals, Rallybio, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies focused on developing biological products, drugs, diagnostics, or platform technologies that address human health and life-science needs. For investors they tend to be high-risk, high-reward securities driven by clinical-trial results, regulatory approvals, patent positions and cash runway, so evaluation emphasizes pipeline prospects, development milestones and partnerships rather than short-term earnings. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Celcuity (CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Read Our Latest Research Report on CELC

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

Rallybio (RLYB)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.

Read Our Latest Research Report on RLYB

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read Our Latest Research Report on MRNA

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.